Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000472940 | SCV000542181 | likely benign | Neurofibromatosis, type 1 | 2024-11-21 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002318512 | SCV000666752 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2023-05-11 | criteria provided, single submitter | clinical testing | The p.V689M variant (also known as c.2065G>A), located in coding exon 18 of the NF1 gene, results from a G to A substitution at nucleotide position 2065. The valine at codon 689 is replaced by methionine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Genome- |
RCV000472940 | SCV002561992 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing |